This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Heart failure	Cardiac myosin	<p><i>In vitro</i> studies suggest that activators of the catalytic domain of cardiac myosin S1 could help treat heart failure. In dogs with heart failure, the cardiac myosin activator omecamtiv mecarbil (CK-1827452) improved cardiac function compared with vehicle control.</p> <p>Omecamtiv mecarbil, a cardiac myosin activator from Cytokinetics Inc. and Amgen Inc., is in Phase II testing to treat heart failure.</p> <p>SciBX 4(13); doi:10.1038/scibx.2011.371 Published online March 31, 2011</p>	Patented by Cytokinetics; exclusively licensed by Amgen	<p>Malik, F.I. <i>et al. Science</i>; published online March 17, 2011; doi:10.1126/science.1200113</p> <p>Contact: Fady I. Malik, Cytokinetics Inc., South San Francisco, Calif. e-mail: fmalik@cytokinetics.com</p>